These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38885312)

  • 1. Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity.
    da Costa AA; Somuncu O; Ravindranathan R; Mukkavalli S; Martignetti DB; Nguyen H; Jiao Y; Lamarre BP; Sadatrezaei G; Moreau L; Liu J; Iyer DR; Lazaro JB; Shapiro GI; Parmar K; D'Andrea AD
    Cancer Res; 2024 Oct; 84(20):3435-3446. PubMed ID: 38885312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
    Lim KS; Li H; Roberts EA; Gaudiano EF; Clairmont C; Sambel LA; Ponnienselvan K; Liu JC; Yang C; Kozono D; Parmar K; Yusufzai T; Zheng N; D'Andrea AD
    Mol Cell; 2018 Dec; 72(6):925-941.e4. PubMed ID: 30576655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks.
    Onji H; Tate S; Sakaue T; Fujiwara K; Nakano S; Kawaida M; Onishi N; Matsumoto T; Yamagami W; Sugiyama T; Higashiyama S; Pommier Y; Kobayashi Y; Murai J
    Oncogene; 2024 Aug; 43(32):2475-2489. PubMed ID: 38961202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.
    Cadzow L; Brenneman J; Tobin E; Sullivan P; Nayak S; Ali JA; Shenker S; Griffith J; McGuire M; Grasberger P; Mishina Y; Murray M; Dodson AE; Gannon H; Krall E; Hixon J; Chipumuro E; Sinkevicius K; Gokhale PC; Ganapathy S; Matulonis UA; Liu JF; Olaharski A; Sangurdekar D; Liu H; Wilt J; Schlabach M; Stegmeier F; Wylie AA
    Cancer Res; 2024 Oct; 84(20):3419-3434. PubMed ID: 39402989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
    Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
    Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA polymerase α-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gaps.
    Machacova Z; Chroma K; Lukac D; Protivankova I; Moudry P
    Nat Commun; 2024 Aug; 15(1):7375. PubMed ID: 39191785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer.
    Simoneau A; Engel JL; Bandi M; Lazarides K; Liu S; Meier SR; Choi AH; Zhang H; Shen B; Martires L; Gotur D; Pham TV; Li F; Gu L; Gong S; Zhang M; Wilker E; Pan X; Whittington DA; Throner S; Maxwell JP; Chen Y; Yu Y; Huang A; Andersen JN; Feng T
    Mol Cancer Ther; 2023 Feb; 22(2):215-226. PubMed ID: 36228090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.
    Taglialatela A; Leuzzi G; Sannino V; Cuella-Martin R; Huang JW; Wu-Baer F; Baer R; Costanzo V; Ciccia A
    Mol Cell; 2021 Oct; 81(19):4008-4025.e7. PubMed ID: 34508659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Xu Z; Li X; Li H; Nie C; Liu W; Li S; Liu Z; Wang W; Wang J
    Oncogene; 2020 Nov; 39(47):7051-7062. PubMed ID: 32989256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
    Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors.
    Xie X; Chen C; Wang C; Guo Y; Sun B; Tian J; Yan J; Li D; Chen G
    Redox Biol; 2024 Oct; 76():103350. PubMed ID: 39265497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USP1-dependent nucleolytic expansion of PRIMPOL-generated nascent DNA strand discontinuities during replication stress.
    Nusawardhana A; Pale LM; Nicolae CM; Moldovan GL
    Nucleic Acids Res; 2024 Mar; 52(5):2340-2354. PubMed ID: 38180818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
    Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition.
    Liu Z; Jiang H; Lee SY; Kong N; Chan YW
    Cell Rep; 2024 Jul; 43(7):114464. PubMed ID: 38985669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATR protects ongoing and newly assembled DNA replication forks through distinct mechanisms.
    Leung W; Simoneau A; Saxena S; Jackson J; Patel PS; Limbu M; Vindigni A; Zou L
    Cell Rep; 2023 Jul; 42(7):112792. PubMed ID: 37454295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
    Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EXO1 and DNA2-mediated ssDNA gap expansion is essential for ATR activation and to maintain viability in BRCA1-deficient cells.
    García-Rodríguez N; Domínguez-García I; Domínguez-Pérez MDC; Huertas P
    Nucleic Acids Res; 2024 Jun; 52(11):6376-6391. PubMed ID: 38721777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
    Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
    Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.